Targeting Cancer Cells With Co(III)-Bipyridyl Complex: A Combined In Vitro and In Silico Study on U87MG and ME-180...

Area of Science:

• Inorganic Chemistry
• Medicinal Chemistry
• Computational Chemistry

Background:

• Enhancing the therapeutic index of cobalt(III) polypyridyl compounds is crucial for anticancer applications.
• Mixed-ligand cobalt(III) complexes offer potential for improved anticancer activity.

Purpose of the Study:

• To synthesize and characterize a new mixed-ligand cobalt(III) complex, [Co^III(Me₂bpy)₂(N₃)₂]⁺.
• To investigate its interaction with DNA and proteins.
• To evaluate its anticancer efficacy and toxicity profile.

Main Methods:

• Synthesis and single crystal X-ray diffraction
• Spectroscopic characterization (UV-Vis, IR)
• Density Functional Theory (DFT) calculations
• Biophysical studies (DNA/HSA binding)
• In silico toxicology assessment
• In vitro MTT cytotoxicity assays

Main Results:

• The novel cobalt(III) complex was successfully synthesized and characterized.
• DFT calculations elucidated metal-ligand bonding and electronic transitions.
• Strong binding affinity with calf thymus DNA (ct-DNA) was observed.
• In silico studies indicated a favorable toxicity profile compared to paclitaxel.
• The complex demonstrated significant dose-dependent cytotoxicity against U87MG and ME-180 cancer cell lines.
• Cervical cancer cells (ME-180) were more susceptible to the complex's cytotoxic effects.

Conclusions:

• The synthesized cobalt(III) complex exhibits potent anticancer activity.
• It shows promise as a chemo-adjuvant for combinatorial cancer therapy due to synergistic effects with paclitaxel.
• Further research into this cobalt(III) complex could lead to novel cancer treatment strategies.